Resources Repository
-
BookPublication 2016Cost-Effectiveness Analysis in Health: A Practical Approach, 3rd Edition
Cost-Effectiveness Analysis in Health provides an introduction to the tools, methods, and procedures used to perform cost-effectiveness research. …
Cost-Effectiveness Analysis in Health provides an introduction to the tools, methods, and procedures used to perform cost-effectiveness research. This third edition contains new discussion on meta-analysis and advanced modeling techniques, a worked example using visual modeling software TreeAge Pro, and updated recommendations from the U.S. Public Health Service's Panel on Cost-Effectiveness in Health and Medicine. The book provides process-specific instruction in a concise, structured format to highlight common methods and techniques for: 1) Developing a thoroughly fleshed-out research project; 2) Working…
Evidence Synthesis | Costing Methods | Policy/Regulation | Preferences/Values | Health Outcomes | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Economics/Finance | Health/Medicine | North America -
BookPublication 2017What's In, What's Out: Designing Benefits for Universal Health Coverage
Many low- and middle-income countries now aspire to universal health coverage, where governments ensure that …
Many low- and middle-income countries now aspire to universal health coverage, where governments ensure that all people have access to the quality health services they need without risk of impoverishment. But for universal health coverage to become reality, the health services offered must be consistent with the funds available-and this implies tough everyday choices for policymakers. This publication argues that the creation of an explicit health benefits plan-a defined list of services that are and are…
Evidence Synthesis | Policy/Regulation | Priority Setting/Ethics | Health Outcomes | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global -
BookPublication 2016Cost-Effectiveness in Health and Medicine, 2nd Edition
This is a revised and expanded edition of the original text on Cost-Effectiveness in Health and Medicine. The …
This is a revised and expanded edition of the original text on Cost-Effectiveness in Health and Medicine. The Second Panel on Cost-Effectiveness in Health and Medicine included experts drawn from academia, healthcare administration, and government. The book offers advice for conducting analyses to improve the allocation of health resources, and is intended for economists, policy analysts, hospital executives, and students across health, business, and humanities disciplines. New components of this edition, include an in-depth review of the past 20…
Costing Methods | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Economics/Finance | Health/Medicine | Global | North America | Europe -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Evidence Synthesis | Costing Methods | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Health Outcomes | Value of Information | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | North America -
ArticlePublication 2022Vaccinations versus Lockdowns to Prevent COVID-19 Mortality
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly …
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly available datasets from the Israeli Ministry of Health were used to model the parameters of the pandemic in Israel. The Oxford COVID-19 Government Response Tracker was used for quantitative data on government policies. Data on the Israeli economy were taken from the Central Bureau of Statistics. The models demonstrate that the first lockdown prevented 1022 COVID-19 deaths at the cost…
Costing Methods | Policy/Regulation | Decision Theory | Health Outcomes | State-Transition | Decision Analysis | Infectious Diseases | Economics/Finance | Government/Law | Health/Medicine | Middle East & North Africa -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Policy/Regulation | Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine | Global | North America -
ArticlePublication 2021Health Opportunity Cost Threshold for CEA in the U.S.
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, …
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, the authors simulated the short-term mortality and morbidity resulting from increased premium related cancelation of insurance coverage. The authors used this model to estimate cost-effectiveness thresholds, in dollars per quality-adjusted life year (QALY) gained based on health opportunity costs. They reported the number of persons who dropped insurance coverage, resulting number of additional deaths and QALYs lost from mortality and…
Evidence Synthesis | Policy/Regulation | Priority Setting/Ethics | Health Outcomes | Microsimulation | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | North America -
BookPublication 2019Non-Communicable Disease Prevention: Best Buys, Wasted Buys, Contestable Buys
Non-communicable diseases (NCDs) are the leading cause of death worldwide, and the majority of these …
Non-communicable diseases (NCDs) are the leading cause of death worldwide, and the majority of these deaths occur in low- and middle-income countries. This book provides practical guidelines and lessons learned through real-world case studies. It is intended to be informative to NCD program managers, policy officers and decision-makers in low- and middle-income countries, who need to comparatively assess interventions for the prevention and control of NCDs.The authors emphasize the importance of context in NCD control…
Policy/Regulation | Priority Setting/Ethics | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Chronic Disease/Risk | Health Systems | Health/Medicine | Global -
ArticlePublication 2018Comparing Cost-per-QALYs Gained to Cost-per-DALYs Averted
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, …
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, the Tufts Medical Center CEA Registry (cost-per-QALY gained studies), and the Global Cost-Effectiveness Analysis (GHCEA) Registry (cost-per-DALY averted studies). Study characteristics that were analyzed included intervention type, sponsor, country, primary disease, and number of CEAs versus disease burden estimates for major conditions. The authors report that cost-per-QALY studies were most often about pharmaceuticals or interventions in high-income countries while cost-per-DALY…
Evidence Synthesis | Policy/Regulation | Cost-Effectiveness Analysis | Health/Medicine | Global